Stock Analiz

Twist Bioscience Corp (TWST) financials: revenue, earnings and cash flow

Fiscal 2017–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Twist Bioscience’s revenue went from $11M in fiscal 2017 to $377M in fiscal 2025, growth of about 55.9% a year.

Net income in fiscal 2025 was -$78M, a net margin of -20.6%; the best year in this period was 2017 with -$59M.

Over the twelve months to September 30, 2026, revenue was $459M and net income -$130M.

Free cash flow was -$76M in fiscal 2025 and positive in 0 of the 9 years shown.

The diluted share count rose 2369% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2017: $11M172018: $25M182019: $54M192020: $90M202021: $132M212022: $204M222023: $245M232024: $313M242025: $377M25$377M
Net income
2017: -$59M172018: -$71M182019: -$108M192020: -$140M202021: -$152M212022: -$218M222023: -$205M232024: -$209M242025: -$78M25-$78M
Free cash flow
2017: -$58M172018: -$70M182019: -$103M192020: -$152M202021: -$139M212022: -$226M222023: -$170M232024: -$69M242025: -$76M25-$76M
EPS (diluted)
2017: $-24489.86172018: $-0.03182019: $-3.92192020: $-3.57202021: $-3.15212022: $-4.04222023: $-3.60232024: $-3.60242025: $-1.3025$-1.30

Income statement

Fiscal yearTTM202520242023202220212020201920182017
Revenue$459M$377M$313M$245M$204M$132M$90M$54M$25M$11M
Gross profit—$191M$133M$90M$84M$52M$29M$7M-$7M-$13M
Operating income—-$136M-$221M-$217M-$235M-$153M-$140M-$109M-$71M-$58M
Net income-$130M-$78M-$209M-$205M-$218M-$152M-$140M-$108M-$71M-$59M
EPS (diluted)$-2.08$-1.30$-3.60$-3.60$-4.04$-3.15$-3.57$-3.92$-0.03$-24489.86
R&D—$80M$91M$107M$120M$69M$43M$36M$20M$19M
Revenue growth—+20.3%+27.7%+20.4%+53.8%+46.9%+65.7%+113.9%+136.2%—

Cash flow

Fiscal yearTTM202520242023202220212020201920182017
Operating cash flow—-$48M-$64M-$142M-$124M-$112M-$142M-$88M-$66M-$51M
Capital spending—-$28M-$5M-$28M-$102M-$27M-$10M-$15M-$4M-$7M
Free cash flow—-$76M-$69M-$170M-$226M-$139M-$152M-$103M-$70M-$58M
Dividends paid—$0$0$0$0$0$0$0$0$0
Buybacks——————————
Stock-based pay—$64M$51M$30M$80M$37M$17M$11M$3M$2M

Balance sheet

Fiscal yearTTM202520242023202220212020201920182017
Cash—$232M$276M$336M$505M$478M$290M$138M$81M$31M
Debt—$76M$85M$94M$95M$63M$36M$8M$10M—
Equity—$473M$473M$623M$789M$581M$336M$152M-$201M-$133M
Total assets—$642M$614M$776M$961M$702M$399M$187M$116M—
Shares (diluted)63M60M58M57M54M48M39M27M3M2M

Margins and returns

Fiscal yearTTM202520242023202220212020201920182017
Gross margin—50.7%42.6%36.6%41.4%39.1%31.9%12.8%-26.6%-123.1%
Operating margin—-36.2%-70.6%-88.6%-115.3%-115.4%-155.5%-200.2%-277.5%-543.2%
Net margin-28.3%-20.6%-66.7%-83.5%-107.0%-114.9%-155.3%-198.0%-280.2%-550.9%
FCF margin—-20.1%-22.1%-69.5%-111.1%-105.3%-168.8%-188.8%-274.7%-537.7%
ROIC—-19.6%-31.3%-23.9%-25.3%-23.4%-29.7%-53.8%——
ROE—-16.4%-44.2%-32.8%-27.6%-26.2%-41.6%-70.8%35.4%44.5%

Frequently asked questions

What is Twist Bioscience’s annual revenue?

$377M in fiscal 2025 and $459M over the twelve months to September 30, 2026.

How much profit does Twist Bioscience make?

Net income was -$78M in fiscal 2025 (net margin -20.6%).

Is Twist Bioscience’s revenue growing?

Yes: revenue rose 20.3% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.